In the race for a Covid-19 vaccine, here come the tortoises
Anyone handicapping the so-called competition to develop vaccines would do well to keep an eye on the players who seemingly got a late start.
Anyone handicapping the so-called competition to develop vaccines would do well to keep an eye on the players who seemingly got a late start.
Amid layoffs and a hit to earnings, Bristol’s new CEO shares his vision for the future.
No one should be forced to choose between the community they call home and being able to access the care their children need.
The dominance of group purchasing organizations (GPOs) is often cited as a cause of generic drug shortages. The problem is more complicated than that.
New research from academic hospitals reveals significant limitations of large language models (LLMs) in medical settings.
Why a British hospital, and not a drugmaker, is trying to get a rare disease therapy approved.
“Colombia is planting a flag for global health equity,” said Peter Maybarduk, who heads the access to medicines campaign at Public Citizen.
Takeda Pharmaceuticals has left BIO, the fourth departure of a major member since December, the company confirmed.
The FTC’s ban on noncompete agreements, approved Tuesday, was immediately challenged in a lawsuit filed in the Eastern District of Texas.
Costs for the U.S. health care system and the federal government will climb thanks to weight loss drugs, two new reports show.
The Supreme Court seemed divided over the Biden administration’s argument that an Idaho abortion ban conflicts with federal law.